Perrigo Company plc (PRGO) — Company Overview

---

Executive Summary

Perrigo Company plc is one of the world's largest manufacturers of store-brand (private-label) over-the-counter (OTC) healthcare and consumer self-care products, alongside a portfolio of branded OTC consumer products including Opill (the first FDA-approved OTC daily oral contraceptive), Mederma, Compeed, ellaOne, and Jungle Formula. Perrigo's core value proposition to retailers is manufacturing "the same product as the national brand, but cheaper" — a scale-driven, low-cost-manufacturing business rather than a high-margin branded-innovation business. Fiscal 2025 was a difficult year: net sales fell to $4.25 billion (down 2.8%) and the company recorded a $1.40 billion net loss from continuing operations, driven primarily by a $1.3 billion goodwill impairment, against a backdrop of soft OTC category consumption and a challenged infant-formula market.

---

1. Core Business Model & How They Work

 Retailer private-label      Branded OTC products      B2B contract
 store-brand programs   ➡️   (Opill, Mederma, etc.) ➡️  manufacturing
        │                          │                         │
        └──────────────┬───────────┴─────────────────────────┘
                        ▼
         Large-scale, low-cost OTC manufacturing network
                        ▼
      Retail self-care aisles (mass, grocery, drug, e-commerce)

Perrigo earns its margin primarily through manufacturing scale and cost efficiency rather than brand pricing power. Roughly two-thirds of its portfolio is store-brand/private-label product sold to major retailers (who then sell it under their own banner at a discount to the national brand), with the remainder split between Perrigo's own consumer brands and contract/other manufacturing.

---

2. Business Segments

As reported for FY2025, Perrigo operated through two primary geographic segments (the company announced a move to new product-based segments — Self Care, Specialty Care, Infant Formula, and Other — beginning in Q1 2026):

• Consumer Self-Care Americas (CSCA) — Net sales of $2.59 billion (down 4.0%), adjusted operating margin of 15.9%. Includes U.S. store-brand OTC, infant formula, and Oral Care. Infant formula and store-brand OTC contract manufacturing were the main drags on growth.
• Consumer Self-Care International (CSCI) — Net sales of $1.67 billion (down 0.7%; +0.3% organic), adjusted operating margin of 21.9%. Covers Europe and other international markets; divestitures reduced reported sales by 4.0%.

The Dermacosmetics business (part of "Other") is being divested for up to €327 million.

---

3. Product Portfolio

---

4. Competitive Landscape

Perrigo competes against both branded OTC manufacturers — Church & Dwight, Prestige Consumer Healthcare, Reckitt Benckiser, Haleon, Kenvue — and other private-label/store-brand manufacturers that compete on the same cost basis. In infant formula, it competes with Reckitt (Mead Johnson) and Abbott, both far larger and more financially resilient. Perrigo's structural disadvantage is that store-brand customers (large retailers) hold significant pricing leverage, and the company has comparatively little pricing power of its own; its advantage is manufacturing scale and breadth across OTC categories that smaller private-label competitors cannot match.

---

5. Strategic Strengths & Risks

Strengths: Broad manufacturing scale across OTC categories; entrenched store-brand relationships with major retailers; a differentiated branded-innovation pipeline (Opill); geographic diversification across the Americas and Europe.

Risks: Heavy reliance on low-margin, low-differentiation store-brand volume; large recent goodwill impairment signals overpaid/underperforming past acquisitions; infant formula is a volatile, reputationally-sensitive category; soft discretionary OTC consumption; retailer concentration gives customers negotiating leverage; ongoing divestiture activity (Dermacosmetics) creates portfolio-transition risk.

---

6. Financial Overview

Source: Perrigo Q4/FY2025 earnings release (investor.perrigo.com, Feb. 26, 2026).

---

7. Summary Conclusion

Perrigo is a scale-manufacturing business in a structurally low-margin, low-pricing-power category (store-brand OTC), with a modest branded-innovation pipeline (Opill) as a partial offset. FY2025 results show real operating headwinds — a large goodwill writedown, declining sales, and soft category consumption — layered on top of an already thin-moat business model. The company's competitive position rests on manufacturing breadth and retailer relationships rather than durable pricing power or switching costs.